Gefitinib vs Gefitinib + Chemo in EGFR-Mutant NSCLC | Long-Term Trial Results Explained

MARIPOSA Study: Resistance to Amivantamab + Lazertinib vs Osimertinib in EGFR+ NSCLC

PALOMA-3: SC vs IV Amivantamab + Lazertinib in EGFR+ NSCLC | Phase 3 OS Results

FLAURA2: TP53 & Resistance in 1L Osimertinib ± Chemo for EGFR+ NSCLC | WCLC 2024 Update

CTONG 2008: 1L Osimertinib ± Savolitinib in MET+EGFRm NSCLC | Phase II Trial Results

UNICORN Trial: 1L Osimertinib in NSCLC With Uncommon EGFR Mutations | Phase 2 Results

MARIPOSA-2: Amivantamab ± Lazertinib + Chemo After Osimertinib in EGFR+ NSCLC | Phase III

HARMONi-A: Ivonescimab + Chemo After EGFR-TKI Progression in NSCLC | Phase 3 Trial Results

Real-World Outcomes: Osimertinib + Pemetrexed-Platinum After 1L Progression in EGFR+ NSCLC

ctDNA-Guided De-Escalation in Advanced NSCLC | Targeted Therapy Trial Results Explained

Understanding EGFR-Mutated Lung Cancer | Diagnosis, Treatment & Latest Advances Explained

TKI + What? Best Combos for Advanced EGFR-Mutant NSCLC | Timing & Evidence Explained

How I have Chosen my Research Topics and What have I learnt from this?

Talk About Lung Connect | Empowering Lung Cancer Care Through Knowledge & Community

Lorlatinib vs Crizotinib in ALK+ NSCLC: 5-Year PFS & Safety Results from the CROWN Study

Lorlatinib AEs After 5 Years: Kinetics & Management in CROWN Study | WCLC MA06.08 Update

Iruplinalkib vs Crizotinib in ALK+ NSCLC: Interim Results from Phase 3 Trial in TKI-Naive Patients

SAF-189s vs Crizotinib in ALK+ NSCLC: Phase III Results | WCLC 2024 OA09.03 Highlights

Lorlatinib in 2nd Line+ for ALK+ Lung Cancer: Real-World Data from Resource-Constrained Settings

Panel Discussion: Based on the Above Topics

A new benchmark in the first line management of ALk+ NSCLC

Adagrasib vs Docetaxel in KRASG12C+ NSCLC w/ Brain Mets | KRYSTAL-12 Results ASCO 2024

Olomorasib + Pembrolizumab/Chemo in KRAS G12C+ NSCLC | 1L Treatment Data from ASCO 2024

Lorlatinib in ROS1+ NSCLC After Crizotinib & Chemo | Phase II MA06.05 Trial (WCLC 2024)

Telisotuzumab Vedotin in Asian C-Met+ EGFR WT NSCLC | LUMINOSITY Trial Results (WCLC 2024)

Encorafenib + Binimetinib in BRAF V600E+ mNSCLC | PHAROS Phase 2 Trial Update (WCLC 2024)

Trastuzumab Deruxtecan in HER2+ NSCLC | DESTINY-Lung03 Part 1 Results (WCLC 2024)

Larotrectinib in TRK Fusion Lung Cancer | Updated Efficacy & Biomarker Data (WCLC 2024)

Expert Panel on KRAS, HER2, TRK, C-Met & ROS1 NSCLC Trials | Key Takeaways from ASCO/WCLC 2024

Rozlytrek in ROS1+ & NTRK+ NSCLC | Targeted Therapy for Fusion-Driven Lung Cancer

TCR Therapy Explained | Basic Structure & Manufacturing Process of T Cell Receptors

Multiple Myeloma Case Study | Diagnosis, Treatment Approach & Clinical Insights (Case 1)

CNS Tumor Case Study | Diagnosis, Imaging & Treatment Insights (Case 2: Neuro-Oncology)

Head & Neck Cancer with Glioma Case Study | Diagnosis & Multidisciplinary Care (Case 3)

Thoracic Tumors Case Study | Diagnosis, Staging & Treatment Strategy (Case 4 Overview)

Gastrointestinal (GI) Tumors Case Study | Diagnosis, Workup & Treatment Plan (Case 5)

Genitourinary (GU) Tumors Case Study | Diagnosis, Staging & Treatment Insights (Case 6)

Gynecologic Cancer & Sarcoma Case Study | Diagnostic & Treatment Approach (Case 7)

Gefitinib vs Gefitinib + Chemo in EGFR-Mutant NSCLC | Long-Term Trial Results Explained

MARIPOSA Study: Resistance to Amivantamab + Lazertinib vs Osimertinib in EGFR+ NSCLC

PALOMA-3: SC vs IV Amivantamab + Lazertinib in EGFR+ NSCLC | Phase 3 OS Results

FLAURA2: TP53 & Resistance in 1L Osimertinib ± Chemo for EGFR+ NSCLC | WCLC 2024 Update

CTONG 2008: 1L Osimertinib ± Savolitinib in MET+EGFRm NSCLC | Phase II Trial Results

UNICORN Trial: 1L Osimertinib in NSCLC With Uncommon EGFR Mutations | Phase 2 Results

MARIPOSA-2: Amivantamab ± Lazertinib + Chemo After Osimertinib in EGFR+ NSCLC | Phase III

HARMONi-A: Ivonescimab + Chemo After EGFR-TKI Progression in NSCLC | Phase 3 Trial Results

Real-World Outcomes: Osimertinib + Pemetrexed-Platinum After 1L Progression in EGFR+ NSCLC

ctDNA-Guided De-Escalation in Advanced NSCLC | Targeted Therapy Trial Results Explained

Understanding EGFR-Mutated Lung Cancer | Diagnosis, Treatment & Latest Advances Explained

TKI + What? Best Combos for Advanced EGFR-Mutant NSCLC | Timing & Evidence Explained

How I have Chosen my Research Topics and What have I learnt from this?

Lorlatinib vs Crizotinib in ALK+ NSCLC: 5-Year PFS & Safety Results from the CROWN Study

Lorlatinib AEs After 5 Years: Kinetics & Management in CROWN Study | WCLC MA06.08 Update

Iruplinalkib vs Crizotinib in ALK+ NSCLC: Interim Results from Phase 3 Trial in TKI-Naive Patients

SAF-189s vs Crizotinib in ALK+ NSCLC: Phase III Results | WCLC 2024 OA09.03 Highlights

Lorlatinib in 2nd Line+ for ALK+ Lung Cancer: Real-World Data from Resource-Constrained Settings

Panel Discussion: Based on the Above Topics

A new benchmark in the first line management of ALk+ NSCLC

Adagrasib vs Docetaxel in KRASG12C+ NSCLC w/ Brain Mets | KRYSTAL-12 Results ASCO 2024

Olomorasib + Pembrolizumab/Chemo in KRAS G12C+ NSCLC | 1L Treatment Data from ASCO 2024

Lorlatinib in ROS1+ NSCLC After Crizotinib & Chemo | Phase II MA06.05 Trial (WCLC 2024)

Telisotuzumab Vedotin in Asian C-Met+ EGFR WT NSCLC | LUMINOSITY Trial Results (WCLC 2024)

Encorafenib + Binimetinib in BRAF V600E+ mNSCLC | PHAROS Phase 2 Trial Update (WCLC 2024)

Trastuzumab Deruxtecan in HER2+ NSCLC | DESTINY-Lung03 Part 1 Results (WCLC 2024)

Larotrectinib in TRK Fusion Lung Cancer | Updated Efficacy & Biomarker Data (WCLC 2024)

Expert Panel on KRAS, HER2, TRK, C-Met & ROS1 NSCLC Trials | Key Takeaways from ASCO/WCLC 2024

Rozlytrek in ROS1+ & NTRK+ NSCLC | Targeted Therapy for Fusion-Driven Lung Cancer

TCR Therapy Explained | Basic Structure & Manufacturing Process of T Cell Receptors

Multiple Myeloma Case Study | Diagnosis, Treatment Approach & Clinical Insights (Case 1)

CNS Tumor Case Study | Diagnosis, Imaging & Treatment Insights (Case 2: Neuro-Oncology)

Head & Neck Cancer with Glioma Case Study | Diagnosis & Multidisciplinary Care (Case 3)

Thoracic Tumors Case Study | Diagnosis, Staging & Treatment Strategy (Case 4 Overview)

Gastrointestinal (GI) Tumors Case Study | Diagnosis, Workup & Treatment Plan (Case 5)

Genitourinary (GU) Tumors Case Study | Diagnosis, Staging & Treatment Insights (Case 6)

Gynecologic Cancer & Sarcoma Case Study | Diagnostic & Treatment Approach (Case 7)